Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment.

MLA

Nogova, Lucia, et al. “Sorafenib and Everolimus in Patients with Advanced Solid Tumors and KRAS-Mutated NSCLC: A Phase I Trial with Early Pharmacodynamic FDG-PET Assessment.” Cancer Medicine, vol. 9, no. 14, July 2020, pp. 4991–5007. EBSCOhost, https://doi.org/10.1002/cam4.3131.

APA

Nogova, L., Mattonet, C., Scheffler, M., Taubert, M., Gardizi, M., Sos, M. L., Michels, S., Fischer, R. N., Limburg, M., Abdulla, D. S. Y., Persigehl, T., Kobe, C., Merkelbach-Bruse, S., Franklin, J., Backes, H., Schnell, R., Behringer, D., Kaminsky, B., Eichstaedt, M., … Wolf, J. (2020). Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. Cancer Medicine, 9(14), 4991–5007. https://doi.org/10.1002/cam4.3131

Chicago

Nogova, Lucia, Christian Mattonet, Matthias Scheffler, Max Taubert, Masyar Gardizi, Martin L Sos, Sebastian Michels, et al. 2020. “Sorafenib and Everolimus in Patients with Advanced Solid Tumors and KRAS-Mutated NSCLC: A Phase I Trial with Early Pharmacodynamic FDG-PET Assessment.” Cancer Medicine 9 (14): 4991–5007. doi:10.1002/cam4.3131.